Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Unleashing the therapeutic potential of oncolytic viruses
Praveen K. Bommareddy, Howard L. Kaufman
Praveen K. Bommareddy, Howard L. Kaufman
Published March 5, 2018
Citation Information: J Clin Invest. 2018;128(4):1258-1260. https://doi.org/10.1172/JCI120303.
View: Text | PDF
Commentary Article has an altmetric score of 16

Unleashing the therapeutic potential of oncolytic viruses

  • Text
  • PDF
Abstract

Oncolytic viruses (OVs) are a versatile new class of therapeutic agents based on native or genetically modified viruses that selectively replicate in tumor cells and can express therapeutic transgenes designed to target cells within the tumor microenvironment and/or host immunity. To date, however, confirmation of the underlying mechanism of action and an understanding of innate and acquired drug resistance for most OVs have been limited. In this issue of the JCI, Zamarin et al. report a comprehensive analysis of an oncolytic Newcastle disease virus (NDV) using both murine melanoma tumor models and human tumor explants to explore how the virus promotes tumor eradication and details of the mechanisms involved. These findings have implications for the optimization of oncolytic immunotherapy, at least that based on NDV, and further confirm that specific combinatorial approaches are promising for clinical development.

Authors

Praveen K. Bommareddy, Howard L. Kaufman

×

Figure 1

Schematic representation of how OVs influence various aspects of the cancer-immunity cycle.

Options: View larger image (or click on image) Download as PowerPoint
Schematic representation of how OVs influence various aspects of the can...
Following tumor infection by an OV, the virus selectively replicates in tumors cells (i). The cells are lysed, resulting in immunogenic cell death and release of soluble virus- and tumor-specific antigens, danger-associated molecular patterns (DAMPs), pathogen-associated molecular patterns (PAMPs), type 1 IFNs, and chemokines (ii), which help recruit and condition professional antigen-presenting cells such as DCs (iii). DCs migrate with antigen to regional lymph nodes, where they prime and activate virus- and tumor-specific T cells (iv). The chemokine gradient generated within the tumor microenvironment recruits antigen-specific T cells (v), and T cells mediate cytotoxic effector functions within the injected tumor (vi). The local cytokine profile can also increase PD-1 expression on T cells and PD-L1 expression on tumor cells (vii) as a counterregulatory measure, limiting immune responses but also rendering the tumors more susceptible to treatment with checkpoint blockade. In contrast to some intratumoral therapies, OVs can also result in trafficking of tumor-specific T cells to distant, uninjected tumors, where they can mediate antitumor activity (viii).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 1 news outlets
Blogged by 1
Posted by 2 X users
Mentioned by 1 peer review sites
27 readers on Mendeley
See more details